Early-onset cancers are on the rise: Knowing family history is crucial
medicalxpress - In the U.S., more than a dozen kinds of cancer are on the rise in adults under 50. Among these early-onset cancers, colorectal and breast cancers have increased the most, and colorectal cancer is now the deadliest cancer for Americans ages 18 to 49.
AI Summary: New analyses show early‑onset cancers are increasing and reinforce that detailed family history remains a key tool for risk assessment and targeted screening. Experts urged clinicians and health systems to prioritize family‑history collection and cascade testing to catch at‑risk individuals sooner and reduce preventable morbidity.
- Breast cancer risk: AI tools, polygenic scores, prevention (5)
- Colorectal cancer: rising cases and screening gaps worldwide (6)
- Faster biological aging linked to early-onset cancer rise (5)
- Inherited cancer risk and genomics driving early diagnoses (6)
- All Other Stories
Breast cancer risk: AI tools, polygenic scores, prevention
Colorectal cancer: rising cases and screening gaps worldwide
Faster biological aging linked to early-onset cancer rise
Inherited cancer risk and genomics driving early diagnoses
All Other Stories
Oldest known plague victims found in a 5,500-year-old burial ground in Siberia — and many of them were children
livescience - The oldest known evidence of the plague killing people has been found in Siberia, and it carried a gene that may have made it particularly deadly for children.
AI Summary: Archaeologists uncovered a 5,500‑year‑old burial site in Siberia containing victims of plague, many of them children, pushing the timeline of Yersinia pestis infections far earlier than previously thought. The discovery provides new clues about ancient disease spread and human vulnerability — and disproves the notion that pandemics are exclusively a modern pastime.
Some tumors eliminate healthy neighboring cells to grow, study reveals
medicalxpress - Chromosomal instability is a common feature in many solid tumors and is associated with greater aggressiveness. For years, its main contribution to cancer was thought to be driving the evolution of tumor genomes, causing cells to gain chromosomes with gro…
AI Summary: Researchers found some tumors actively eliminate neighboring healthy cells to expand and thrive, revealing a brutal but precise survival strategy. Understanding the molecular signals that drive this local cell clearance exposes new therapeutic targets — flip the mechanism and you may stop tumors in their tracks, or at least make cancer's arrogance its downfall.
In a First, Scientists Precisely Edit Human Embryo Genes
Carl Zimmer / nytimes - Researchers relied on a newer gene-editing technique that may make it possibl to engineer embryos, a prospect that has long alarmed bioethicists.
AI Summary: Researchers report the first precise edits to human embryo genes, demonstrating a technical milestone that immediately reopened the ethical and safety conversation about germline modification. Scientists urge caution, tighter oversight and more study before any clinical application while bioethicists debate whether we’ve crossed a line that’s been long teased in science fiction.
LIBRETTO-432 Trial at ASCO 2026 Plenary Session: Adjuvant Selpercatinib in RET Fusion-Positive NSCLC
oncodaily - LIBRETTO-432 Trial was presented during ASCO 2026 by Jonathan W. Goldman, MD, as a global, multicenter, phase 3, double-blind, randomized, placebo-controlled study evaluating adjuvant selpercatinib in patients with early-stage RET […]
AI Summary: At ASCO26 plenary, LIBRETTO‑432 data show adjuvant selpercatinib markedly prolongs event‑free survival and slashes recurrence risk for patients with stage II–IIIA RET fusion–positive non‑small cell lung cancer after curative treatment. The findings support a new standard for this rare genetic subgroup and press the case for routine genomic testing.
One-time gene editing treatment lowers 'bad' cholesterol by up to 62%
medicalxpress - Patients in London have received a pioneering new gene editing therapy that lowers "bad" cholesterol after a single infusion, as part of a study involving UCL scientists.
AI Summary: Early clinical data show a one‑time gene‑editing infusion can reduce LDL cholesterol by as much as 62% in patients with severe hypercholesterolemia. The approach, still experimental, produced large lipid drops with early safety signals, hinting at a possible future one‑and‑done therapy for high‑risk cardiovascular patients — pending larger trials and careful long‑term follow‑up.
OPTIMA: Prosigna-Guided Chemotherapy Avoidance Shows Non-Inferior Outcomes in ER+/HER2− Early Breast Cancer
oncodaily - OPTIMA is one of the most important de-escalation studies presented at the 2026 ASCO Annual Meeting, because it addresses a daily clinical dilemma in early breast cancer: which patients truly […]
AI Summary: The OPTIMA trial demonstrated that using the Prosigna genomic test to select low‑risk ER+/HER2− early breast cancer patients allows omission of adjuvant chemotherapy without compromising disease control. The de‑escalation approach reduced exposure to chemo toxicity and supports molecular risk stratification to spare large numbers of patients unnecessary treatment — elegant, evidence‑based thrift.
Listen to the Latest ‘KFF Health News Minute’
kffhealthnews - The "KFF Health News Minute" brings original health care and health policy reporting from our newsroom to the airwaves each week.
AI Summary: A phase 2 study investigated FGFR inhibition with rogaratinib in succinate dehydrogenase–deficient gastrointestinal stromal tumors. Results reported tumor control in this rare molecular subset, offering a targeted therapeutic approach where options are sparse and validating FGFR as a biologic vulnerability in SDH‑deficient GIST.
Simple blood test could lead to personalized lung cancer treatment
medicalxpress - A single blood test could help doctors predict how lung cancer patients will respond to treatment before therapy begins, researchers have found. University of Queensland-led research focused on non-small cell lung cancer (NSCLC), the most common form of t…
AI Summary: Researchers describe a circulating cell-free methylated DNA liquid biopsy that can detect and track lung cancer by reading tumor-specific methylation patterns in blood. The minimally invasive test aims to guide personalized treatment choices, enable earlier detection of recurrence, and reduce dependence on tissue biopsies—basically doing the diagnostic heavy lifting while you sip your coffee.
- Blood tests for monitoring and personalizing lung cancer care (4)
- MCED trials and clinical benefit debate (4)
- Methylation liquid biopsy methods and applications (4)
- All Other Stories
Blood tests for monitoring and personalizing lung cancer care
MCED trials and clinical benefit debate
Methylation liquid biopsy methods and applications
All Other Stories
How state laws can stymie research into your ancestors' psychiatric records
abcnews - Frustrated family members and others have been pushing for law changes in New York and other states that would allow the release of mental health records of long-dead ancestors
AI Summary: Legal researchers warn that a patchwork of state statutes and privacy rules is blocking access to historical psychiatric records needed for family‑history and population‑level studies. The restrictions complicate efforts to understand intergenerational mental‑health patterns and hamper reproducible research, leaving scientists to navigate inconsistent consent, archival access, and litigation risks.
Deadly, highly venomous box jellyfish discovered near Singapore is a newfound species
livescience - Researchers identified a new species of box jellyfish and recorded a surprising range expansion for the Thai sea wasp after analyzing the morphology and DNA of a handful of jellies in Singapore.
AI Summary: Marine scientists have identified a previously unknown species of highly venomous box jellyfish off Singapore, based on morphological and genetic analyses. The finding expands knowledge of regional marine biodiversity and triggers public‑safety updates and clinical guidance for envenomation, because nothing says “summer beach read” like a creature that can ruin your day.
Overactive MYC helps tumors fix DNA breaks and resist chemotherapy, study finds
medicalxpress - A protein best known for driving cancer growth also helps damaged tumor cells survive by repairing their DNA, according to a new study that could influence how some cancers are treated.
AI Summary: New research reveals overactive MYC drives tumor cells to repair DNA breaks more efficiently, enabling resistance to chemotherapy. By illuminating the repair pathways MYC hijacks, the study identifies potential targets to reverse resistance and improve treatment responses — because apparently cancers read the manual on how to survive your best shot.
- MYC hijacks DNA repair to enable chemo resistance (4)
- Other molecular drivers of chemoresistance and genome instability (3)
- Tumor cell death and immunity shape chemotherapy outcomes (3)
- All Other Stories
MYC hijacks DNA repair to enable chemo resistance
Other molecular drivers of chemoresistance and genome instability
Tumor cell death and immunity shape chemotherapy outcomes
All Other Stories
Data-Driven Decision Support in Obesity Management Commission: enabling more equitable and personalized obesity care
Paul W. Franks / nature - Nature Medicine, Published online: 12 May 2026; doi:10.1038/s41591-026-04363-0Announced in this Comment and in collaboration with Nature Medicine is the convening of the Data-Driven Decision Support in Obesity Management Commission, to promote adequate sc…
AI Summary: A phase 1/2 study of CRISPR‑Cas9 CD33‑deleted allogeneic hematopoietic cell transplantation followed by gemtuzumab ozogamicin maintenance reports encouraging early signals in AML. The gene‑editing approach aims to protect donor cells from CD33‑targeted therapy, potentially enabling safer post‑transplant maintenance and offering a novel strategy to marry cellular engineering with targeted antibody therapy.
- CD33‑targeted transplant and post‑transplant maintenance (4)
- Safety and ethical scrutiny of gene editing and gene therapy (3)
- Scaling cell therapy: accreditation and expanding CAR indications (3)
- All Other Stories
CD33‑targeted transplant and post‑transplant maintenance
Safety and ethical scrutiny of gene editing and gene therapy
Scaling cell therapy: accreditation and expanding CAR indications
All Other Stories
Historical DNA Links Colonial Graves to 1.3 Million Living Relatives and May Have Identified the Colony’s Second Governor
discovermagazine - Learn how researchers used DNA and 23andMe to connect 17th-century Maryland colonists to more than 1.3 million living people and potentially identify the colony’s second governor.
AI Summary: Ancient DNA from a colonial‑era burial site has been analyzed and linked to living descendants, potentially identifying one of the colony’s leaders. Among the finds is an 8‑year‑old African American boy buried with white colonists; researchers report his presence but cannot yet determine whether he was enslaved, prompting fresh questions about social status and burial practices.
Personalized Brain Cancer Vaccine May Help Against Aggressive Glioblastoma
discovermagazine - Discover how a personalized DNA vaccine trained patients’ immune systems to target their own tumors, with one participant remaining cancer-free nearly five years later.
AI Summary: A customized vaccine targeting each patient's tumor has demonstrated encouraging immune responses and signs of clinical benefit against aggressive glioblastoma. Researchers report enhanced T‑cell activity and preliminary survival signals, suggesting personalized neoantigen vaccines may help control this stubborn brain cancer and warrant larger, controlled trials to confirm impact.
- New models and datasets speeding brain tumor research (3)
- Next-gen glioblastoma immunotherapies: CAR T, drugs, stem cells (3)
- Personalized glioblastoma vaccine: early immune and survival signals (3)
- All Other Stories
New models and datasets speeding brain tumor research
Next-gen glioblastoma immunotherapies: CAR T, drugs, stem cells
Personalized glioblastoma vaccine: early immune and survival signals
All Other Stories
A Cancer Driven by Ultra-Rare Mutation Gets Its First FDA-Approved Therapy
Frank Vinluan / medcitynews - Partner Therapeutics’ Bizengri is now FDA approved for treating advanced cases of cholangiocarcinoma driven by NRG1 gene fusions. Partner acquired U.S. rights to this bispecific antibody from Merus in 2024. The post A Cancer Driven by Ultra-Rare Mutation …
AI Summary: The FDA approved zenocutuzumab‑zbco for NRG1‑fusion–positive cholangiocarcinoma, delivering the first cleared therapy for cancers driven by this ultra‑rare genomic alteration. Trial data showed meaningful responses in heavily pretreated patients, prompting regulators to greenlight a precision option that offers targeted benefit where none existed — a small‑population win for genomic oncology.
Study reveals how parenting styles shape babies' willingness to help others
medicalxpress - New research from Durham University shows that the way parents instruct and encourage infants to help plays a key role in how helping behavior develops, and that these approaches vary across cultures.
AI Summary: The RESET‑C trial tested one preoperative dose of pembrolizumab in localized mismatch repair‑deficient colon cancer and recorded unexpectedly high tumor responses, with several patients remaining cancer‑free for nearly three years. The dramatic neoadjuvant activity suggests immune priming could reshape perioperative strategies and raises questions about surgery timing and organ preservation.
National study examines genetic testing to inform follow-up care for cancer survivors
medicalxpress - Hundreds of thousands of people diagnosed with cancer are still alive today but were never genetically tested, either because testing was not available or was not routinely offered at the time of their diagnosis. These patients are just as likely as those…
AI Summary: A national study has been launched to assess whether genetic testing can refine follow-up care for cancer survivors, tailoring surveillance to individual risk and potentially reducing unnecessary tests. The large-scale effort seeks to integrate genomic data into survivorship plans to better predict late effects and allocate resources to those most likely to benefit.
- Building survivorship standards, care and advocacy (4)
- Conferences, research and personalized cancer survivorship insights (4)
- National genetic-testing study and genomic implications for survivors (4)
- All Other Stories
Building survivorship standards, care and advocacy
Conferences, research and personalized cancer survivorship insights
National genetic-testing study and genomic implications for survivors
All Other Stories
First-Ever Smell Map Is a Breakthrough in Sensory Research, a Step to Help Us Tackle Loss of Smell
discovermagazine - Discover how smell receptors in our noses aren’t randomly arranged but are highly organized, offering new paths toward treating sensory impairment.
AI Summary: Scientists have produced the first high‑resolution olfactory map, charting how scent receptors and neural circuits are organized in the nose. The atlas exposes unexpected patterns in odor encoding, helps explain smell loss, and points to new diagnostic and therapeutic pathways — including potential early markers of Alzheimer’s‑related olfactory damage.
- Hidden nose atlas rewrites smell organization, flags Alzheimer links (4)
- New brain markers and tests for early Alzheimer detection (4)
- All Other Stories
Hidden nose atlas rewrites smell organization, flags Alzheimer links
New brain markers and tests for early Alzheimer detection
All Other Stories
Preclinical evaluation of antisense oligonucleotide therapy in a mouse model of HNRNPH2-related neurodevelopmental disorder
Ane Korff, Xiaojing Yang, Ozan Ozdemir, Ananya Samanta, Yong-Dong Wang, Tushar Patni, Alfonso J. Lav / science - Science Translational Medicine, Volume 18, Issue 846, April 2026.
AI Summary: Researchers report that antisense oligonucleotide therapy reversed neurological deficits in mouse models of HNRNPH2‑related neurodevelopmental disorder. The preclinical results provide a targeted mechanism to correct pathogenic RNA processing, moving a once‑untreatable condition toward a plausible therapeutic path — pending the usual caution about translating mice to humans.